4D pharma To Stop Testing Asthma Med in COVID-19 Patients

• 4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma.

• Following the completion of enrollment of Part A, the company expects to announce topline results from these patients in the second half of 2021.

• Citing higher vaccination rates, the company also voluntarily discontinued the enrollment in the Phase 2 study of MRx-4DP0004 to treat hospitalized patients with COVID-19 in the U.K. to focus on its core pipeline candidates.

• MRx-4DP0004 is an oral, immunomodulatory, single strain LBP. 4D pharma has demonstrated MRx-4DP0004's ability to reduce airway inflammation in a pre-clinical model of severe asthma.

• It is achieved through a concurrent reduction in both neutrophilic and eosinophilic infiltration and inflammation.

• Price Action: LBPS shares are down 1.3% at $10.53 during the market session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• 4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.